AI is reshaping quality, regulatory, and manufacturing operations faster than the rulebooks can keep up. For product companies operating under FDA oversight, the question is no longer whether to adopt AI, but how to do it without creating the next warning letter.
At Propulsion 2026, Propel CRO Zack Jha, KPMG's Life Sciences Quality and Regulatory Practice Lead Rajesh Misra, and industry veteran Zak Macht sat down for a frank conversation with moderator Dario Ambrosini about what it actually takes to deploy AI responsibly in regulated environments. From a real FDA warning letter triggered by an AI agent that failed to flag a missing process validation, to the future of real-time batch release and AI-powered post-market surveillance, this session covers the full landscape.
Rajesh issues a challenge to stop chasing incremental wins and pursue the kind of bold, business-transforming AI use cases that can deliver 20-30% bottom-line impact. Zack grounds that ambition with a hard-won caution from the cloud era: know your costs before your CFO gets surprised. And across the board, the panel agrees that the companies building AI into the fabric of their QMS, not bolting it on as a side project, are the ones that will come out ahead.







